The combination of asthma and being a carrier of genetic variants (mutations and / or polymorphisms) in the CFTR gene variant would cause bronchial asthma with mucus hypersecretion. This phenotype is characterized by a more severe disease, in terms of control, quality of life, exacerbations and lung function, and a different asthma the bronchial hypersecretion without inflammatory phenotype.

开始日期2015-05-01

申办/合作机构-

100 项与马来酸氯苯那敏/那可丁/二羟丙茶碱/盐酸甲氧那明相关的临床结果

登录后查看更多信息

100 项与马来酸氯苯那敏/那可丁/二羟丙茶碱/盐酸甲氧那明相关的转化医学

登录后查看更多信息

100 项与马来酸氯苯那敏/那可丁/二羟丙茶碱/盐酸甲氧那明相关的专利（医药）

登录后查看更多信息

项与马来酸氯苯那敏/那可丁/二羟丙茶碱/盐酸甲氧那明相关的文献（医药）

2022-02-01·Tissue and Cell4区 · 生物学

Emodin inhibits NF-κB signaling pathway to protect obese asthmatic rats from pathological damage via Visfatin

4区 · 生物学

Article

作者: He, Xiaoming ; Cai, Wanru ; Hu, Jiang ; Miao, Jing

PURPOSEEmodin has a protective effect on asthma. Obesity is closely related to asthma. We further explored the role of Emodin in obese asthmatic rats.METHODSOvalbumin (OVA) was used to induce asthma model, and high fat diet (HFD) was used to induce obese rat model. Body weight was measured before and after the modeling. Serum lipid levels were evaluated using commercial kits. Then, lung tissue and airway tissue of rat were separated forin vivo. Hematoxylin-eosin staining (HE) analyzed the extent of lung lesions. Quantitative reverse transcription PCR assessed the mRNA expression of Visfatin and Enzyme linked immunosorbent assay measured NF-κB protein expression in airway tissues. MTT, Brdu and Western blot detected cell viability, proliferation and NF-κB level of human bronchial epithelial cells 16HBE, respectively.RESULTSAsthma and Emodin alone had no effect on the body weight of normal rats, while HFD promoted the body weight of rats and could be reversed by Emodin. Both asthma and obesity promoted the pathological damage of rat lungs, including emphysema, lipid accumulation, edema changes, lymphoid hypertrophy and airway smooth muscle hyperplasia as well as lipid accumulation in surum, and Emodin treatment could reduce the damage. In the airway tissues of asthma and obesity models, up-regulated Visfatin mRNA and NF-κB protein were observed. In 16HBE, Emodin reversed Visfatin's role in promoting cell viability, proliferation and activating NF-κB signaling pathway.CONCLUSIONEmodin inhibited NF-κB expression to relieve the pathological symptoms of obese asthmatic rats by Visfatin.

2021-03-01·Chest

Adherence to Asthma Biologics

Article

作者: Molly M. Jeffery ; Jacob T. Maddux ; Matthew A. Rank ; Regina W. Lam ; Nilay D. Shah ; Jonathan W. Inselman

BACKGROUNDLittle is known about adherence to asthma biologics.RESEARCH QUESTIONIs adherence to inhaled corticosteroid (ICS) associated with subsequent asthma biologic adherence?STUDY DESIGN AND METHODSWe analyzed individuals with asthma who started asthma biologics in the OptumLab Data Warehouse and used that data until October 2019. We calculated proportion days covered (PDC) for ICS ± long-acting β-agonists in the 6 months before and after asthma biologics were started and asthma biologic PDC for the first 6 months of use. We performed a multivariable analysis to identify factors associated with asthma biologic PDC ≥0.75, ICS PDC ≥0.75 during the 6-month period after asthma biologic were started, and achievement of a ≥50% reduction in asthma exacerbations during the first 6 months of asthma biologic use.RESULTSWe identified 5,319 people who started asthma biologics. The mean PDC for asthma biologics was 0.76 (95% CI, 0.75-0.77) in the first 6 months after starting, higher than the mean PDCs for ICS in the 6 months before (0.44 [95% CI, 0.43-0.45]) and after (0.40 [95% CI, 0.39-0.40]) starting the asthma biologic. PDC ≥0.75 for ICS 6 months before index biologic use is associated with PDC for asthma biologics ≥0.75 (OR, 1.25; 95% CI, 1.10-1.43) and for ICS during the first 6 months of biologic use (OR, 9.93; 95% CI, 8.55-11.53). Neither ICS PDC ≥0.75 (OR, 0.92; 95% CI, 0.74-1.14) nor asthma biologic PDC ≥0.75 (OR, 1.15; 95% CI, 0.97-1.36) is associated with a statistically significant reduction in asthma exacerbations during the first 6 months of asthma biologic use among people with any exacerbation in the 6 months before first use.INTERPRETATIONAdherence to asthma biologic is higher than to ICS and is associated with different factors.

2017-11-01·Nature Reviews Neurology1区 · 医学

Asthma drug could protect against PD

1区 · 医学

Article

作者: Ridler, Charlotte

100 项与马来酸氯苯那敏/那可丁/二羟丙茶碱/盐酸甲氧那明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	R06AB54 R03DA51	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
气道阻塞	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2009-06-30
哮喘	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2009-06-30
慢性支气管炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2009-06-30
普通感冒	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2009-06-30
咳嗽	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2009-06-30